AstraZeneca has announced the launch of AstraZeneca Direct, an online platform designed to create a convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery.
AstraZeneca Direct will support people living with chronic conditions such as asthma, diabetes, heart failure and chronic kidney disease, as well as people seeking flu protection.
AstraZeneca Direct can be accessed directly at AstraZenecaDirect.com starting Wednesday, October 1st, 2025.
Eligible patients with prescriptions for AIRSUPRA (albuterol/budesonide) or FARXIGA (dapaglifozin) will be able to use AstraZeneca Direct to purchase these medicines directly for a cash price up to 70% off the list price.
Additionally, patients will also be able to order FLUMIST (Influenza Vaccine Live, intranasal) for home delivery through the online platform.
Joris Silon, US Country President, AstraZeneca, said: "We remain deeply committed to improving accessibility, affordability and driving innovation in healthcare."
"We are excited to launch AstraZeneca Direct, which will give patients a transparent cash price with the convenience of home delivery."
"The programme complements our existing patient support services and is an important step forward in offering patients the medication they need, when and how they need it."
AstraZeneca Direct is an extension of the company’s longstanding US patient support offerings, which will continue unchanged for eligible patients.
These programmes help a significant number of eligible patients access their prescribed AstraZeneca medication at no or reduced cost.